Recent News

• 04.25.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.14.2025 - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma
• 04.10.2025 - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
• 04.01.2025 - IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events
• 03.31.2025 - IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
• 03.28.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.26.2025 - IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor
• 03.03.2025 - IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets
• 02.28.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.02.2025 - 8-K Current report
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - S-8 Securities to be offered to employees in employee benefit plans